Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade B 66.17 0.44% 0.29
GILD closed up 0.44 percent on Tuesday, September 17, 2019, on 84 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Flat
See historical GILD trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Fell Below 200 DMA Bearish 0.44%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.44%
NR7 Range Contraction 0.44%
Overbought Stochastic Strength 0.44%
200 DMA Support Bullish -1.09%
Upper Bollinger Band Walk Strength -1.09%
Overbought Stochastic Strength -1.09%

Older signals for GILD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis Cardiovascular Diseases HIV Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases AIDS Gilead Sciences Prodrugs Cytomegalovirus Retinitis Fungal Infections Liver Disease Tenofovir Disoproxil
Is GILD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 79.61
52 Week Low 60.32
Average Volume 5,749,475
200-Day Moving Average 65.9402
50-Day Moving Average 65.1902
20-Day Moving Average 64.639
10-Day Moving Average 65.853
Average True Range 1.3551
ADX 19.61
+DI 23.1154
-DI 18.8415
Chandelier Exit (Long, 3 ATRs ) 64.0947
Chandelier Exit (Short, 3 ATRs ) 66.2553
Upper Bollinger Band 67.9056
Lower Bollinger Band 61.3724
Percent B (%b) 0.73
BandWidth 10.107211
MACD Line 0.5289
MACD Signal Line 0.2059
MACD Histogram 0.323
Fundamentals Value
Market Cap 86.42 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 7.18
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 3.14%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 67.61
Resistance 3 (R3) 67.47 66.86 67.37
Resistance 2 (R2) 66.86 66.49 66.93 67.29
Resistance 1 (R1) 66.51 66.26 66.69 66.65 67.21
Pivot Point 65.90 65.90 65.98 65.97 65.90
Support 1 (S1) 65.55 65.53 65.73 65.69 65.13
Support 2 (S2) 64.94 65.30 65.01 65.05
Support 3 (S3) 64.59 64.94 64.97
Support 4 (S4) 64.73